文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

验证出生后生长与早产儿视网膜病变筛查标准

Validation of the Postnatal Growth and Retinopathy of Prematurity Screening Criteria.
PubMed 文献 · JAMA Ophthalmol · 2020-01-01

本研究为前瞻性验证队列研究(G-ROP-2),纳入美国与加拿大41家医院的3981例有早产儿视网膜病变(ROP)风险的早产儿,评估G-ROP筛查标准对1型ROP的敏感性与减少需检查婴儿数的效果。结果显示G-ROP标准预测219/219例1型ROP(敏感性100%,95%CI 98.3%-100%),减少35.6%的婴儿接受检查(n=1418)。

要点

  • G-ROP标准在验证队列中预测219/219例1型ROP,敏感性100%(95%CI 98.3%-100%)。
  • G-ROP标准使接受检查的婴儿数减少35.6%(n=1418)。
  • 合并队列11463例中,G-ROP标准预测677/677例1型ROP(敏感性100%,95%CI 99.4%-100%),减少32.5%接受检查(n=3730)。

核心结论

  • G-ROP筛查标准在验证中具有可推广性,若在美国和加拿大临床使用可减少接受检查的婴儿数。
  • 大型G-ROP队列提供的循证筛查标准对1型ROP的敏感性和特异性(更少婴儿接受检查)均高于当前推荐指南。

研究设计与样本

  • 前瞻性验证队列研究(G-ROP-2),于2015年9月8日至2017年6月13日在美国和加拿大41家医院(25家G-ROP-1医院和16家新医院)开展。
  • 纳入3981例有ROP风险且ROP结局已知的早产儿,其中女孩1878例、男孩2103例,中位胎龄28周(范围22-35周),中位出生体重1072克(范围350-4080克)。

主要发现

  • 在3981例婴儿中,G-ROP标准正确预测219/219例1型ROP,敏感性100%(95%CI 98.3%-100%),同时减少35.6%的婴儿接受检查(n=1418)。
  • 在G-ROP-1与G-ROP-2合并队列11463例婴儿中,G-ROP标准预测677/677例1型ROP,敏感性100%(95%CI 99.4%-100%),减少32.5%的婴儿接受检查(n=3730)。
  • 同一合并队列中,当前标准(出生体重<1501克或胎龄≤30周0天)预测674/677例1型ROP,敏感性99.6%(95%CI 98.7%-99.8%)。

关键数值与推荐

  • G-ROP筛查标准:满足以下1条及以上者接受检查:胎龄小于28周或出生体重小于1051克;在10至19日龄期间体重增长小于120克、在20至29日龄期间体重增长小于180克、或在30至39日龄期间体重增长小于170克;或脑积水。
  • 当前推荐标准为出生体重<1501克或胎龄≤30周0天。

临床怎么用

  • 原文结论指出G-ROP筛查标准在验证中具有可推广性,若在美国和加拿大临床使用可减少接受检查的婴儿数。
  • 原文结论指出G-ROP队列提供的循证筛查标准对1型ROP的敏感性和特异性(更少婴儿接受检查)均高于当前推荐指南。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The first Postnatal Growth and Retinopathy of Prematurity Study (G-ROP-1) developed new screening criteria with 100% sensitivity for type 1 retinopathy of prematurity (ROP) and 30% reduction of infants requiring examinations in a retrospective development cohort of 7483 infants from 29 North American hospitals in 2006-2012. Infants meeting 1 or more of the following criteria undergo examinations: gestational age less than 28 weeks or birth weight less than 1051 g; weight gain less than 120 g during age 10 to 19 days, weight gain less than 180 g during age 20 to 29 days, or weight gain less than 170 g during age 30 to 39 days; or hydrocephalus. OBJECTIVE: To evaluate the generalizability of the G-ROP screening criteria in a new cohort of at-risk infants. DESIGN, SETTING, AND PARTICIPANTS: This prospective validation cohort study (G-ROP-2) was conducted at 41 hospitals in the United States and Canada (25 G-ROP-1 hospitals and 16 new hospitals) from September 8, 2015, to June 13, 2017, among 3981 premature infants at risk for ROP and with known ROP outcomes. MAIN OUTCOMES AND MEASURES: Sensitivity for Early Treatment for Retinopathy of Prematurity Study type 1 ROP and potential reduction in infants receiving examinations. RESULTS: Among the 3981 infants in the study (1878 girls and 2103 boys; median gestational age, 28 weeks [range, 22-35 weeks]; median birth weight, 1072 g [range, 350-4080 g]; 1966 white; 942 black; 321 Latino; 120 Asian; 22 Native Hawaian or Pacific Islander; and 25 American Indian or Alaskan Native), the G-ROP criteria correctly predicted 219 of 219 cases of type 1 ROP (sensitivity, 100%; 95% CI, 98.3%-100%), while reducing the number of infants undergoing examinations by 35.6% (n = 1418). In a combined G-ROP-1 and G-ROP-2 cohort of 11 463 infants, the G-ROP criteria predicted 677 of 677 cases of type 1 ROP (sensitivity, 100%; 95% CI, 99.4%-100%), reducing the number of infants receiving examinations by 32.5% (n = 3730), while current criteria (birth weight <1501 g or gestational age ≤30 weeks 0 days) predicted 674 of 677 type 1 cases (sensitivity, 99.6%; 95% CI, 98.7%-99.8%). CONCLUSIONS AND RELEVANCE: This study found that the G-ROP screening criteria were generalizable on validation and, if used clinically in the United States and Canada, could reduce the number of infants receiving examinations. The large G-ROP cohorts provide evidence-based screening criteria that have higher sensitivity and higher specificity (fewer infants receiving examinations) for type 1 ROP than currently recommended guidelines.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Binenbaum G, Tomlinson LA, de Alba Campomanes AG, et al. Validation of the Postnatal Growth and Retinopathy of Prematurity Screening Criteria. JAMA Ophthalmol. 2020. PMID: 31725856. doi:10.1001/jamaophthalmol.2019.4517

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。